![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Dehua Zhao, Jing Chen, Mingming Chu, Xiaoqing Long & Jisheng Wang. (2020) Pharmacokinetic-Based Drug–Drug Interactions with Anaplastic Lymphoma Kinase Inhibitors: A Review. Drug Design, Development and Therapy 14, pages 1663-1681.
Read now
Read now
Ittai B Muller, Adrianus J de Langen, Elisa Giovannetti & Godefridus J Peters. (2017) Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib. OncoTargets and Therapy 10, pages 4535-4541.
Read now
Read now
Srividya Srinivasamaharaj, Bilal Khameze Salame, Jorge Rios-Perez, Goetz Kloecker & Cesar A. Perez. (2016) The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer. Expert Review of Anticancer Therapy 16:12, pages 1227-1233.
Read now
Read now
Ittai B Muller, Adrianus J De Langen, Richard J Honeywell, Elisa Giovannetti & Godefridus J Peters. (2016) Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib. Expert Review of Anticancer Therapy 16:2, pages 147-157.
Read now
Read now
Liting Guo, Haijun Zhang, Weiwei Shao & Baoan Chen. (2015) Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer. Drug Design, Development and Therapy 9, pages 5491-5497.
Read now
Read now
Godefridus J Peters & Richard J Honeywell. (2015) Drug transport and metabolism of novel anticancer drugs. Expert Opinion on Drug Metabolism & Toxicology 11:5, pages 661-663.
Read now
Read now
Articles from other publishers (29)
Anthia Monribot, Olivier Huillard, Nihel Khoudour, Laure‐Hélène Préta, Benoit Blanchet, Laure Cabanes, Rui Batista, Nicolas Pallet, Laurent Chouchana, François Goldwasser, Philippe Sogni & Audrey Thomas‐Schoemann. (2023) Cardiac toxicity associated with pharmacokinetic drug–drug interaction between crizotinib and sofosbuvir/velpatasvir: A case report. British Journal of Clinical Pharmacology 89:4, pages 1486-1490.
Crossref
Crossref
Ahmed A. Abdelgalil & Hamad M. Alkahtani. 2023.
135
166
.
Ahmed A. Abdelgalil & Hamad M. Alkahtani. 2023.
39
69
.
Ammara Siddique, Samra Bashir & Mateen Abbas. 2023. Therapeutic Approaches in Cancer Treatment. Therapeutic Approaches in Cancer Treatment
141
175
.
Puyuan Xing, Qian Zhao, Li Zhang, Hanping Wang, Dingzhi Huang, Pei Hu, Yinghui Sun & Yuankai Shi. (2022) Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study. BMC Medicine 20:1.
Crossref
Crossref
Stefano Fogli, Fabrizio Tabbò, Annalisa Capuano, Marzia Del Re, Francesco Passiglia, Federico Cucchiara, Cristina Scavone, Veronica Gori, Silvia Novello, Manuela Schmidinger & Romano Danesi. (2022) The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences. Critical Reviews in Oncology/Hematology 172, pages 103602.
Crossref
Crossref
Sreemoyee Chatterjee, Shalini Jain, Ritu Jangid & Mukesh Kumar Sharma. 2022.
225
258
.
Gaby A. M. Eliesen, Hedwig van Hove, Maartje H. Meijer, Petra H. H. van den Broek, Jeanne Pertijs, Nel Roeleveld, Joris van Drongelen, Frans G. M. Russel & Rick Greupink. (2020) Toxicity of anticancer drugs in human placental tissue explants and trophoblast cell lines. Archives of Toxicology 95:2, pages 557-571.
Crossref
Crossref
Shangying Chen, Sheng Yong Yang, Xian Zeng, Feng Zhu, Ying Tan, Yu Yang Jiang & Yu Zong Chen. (2020)
Combining kinase inhibitors for optimally
co‐targeting
cancer and drug escape by exploitation of drug target promiscuities
. Drug Development Research 82:1, pages 133-142.
Crossref
Crossref
Richard J. Honeywell, Ietje Kathmann, Elisa Giovannetti, Carmelo Tibaldi, Egbert F. Smit, Maria N. Rovithi, Henk M.W. Verheul & Godefridus J. Peters. (2020) Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance. Cancers 12:11, pages 3322.
Crossref
Crossref
Bruno Revol, Elodie Gautier‐Veyret, Capucine Arrivé, Nathalie Fouilhé Sam‐Laï, Anne McLeer‐Florin, Hélène Pluchart, Julian Pinsolle & Anne‐Claire Toffart. (2019) Pharmacokinetic herb‐drug interaction between ginger and crizotinib. British Journal of Clinical Pharmacology 86:9, pages 1892-1893.
Crossref
Crossref
Abigail R. Bland, Nensi Shrestha, Rhonda J. Rosengren & John C. Ashton. (2020) Does Crizotinib Auto-Inhibit CYP3A in vivo?. Pharmacology 105:11-12, pages 715-718.
Crossref
Crossref
Wenying Shu, Lei Ma, Xiaoye Hu, Meimei Zhang, Wensheng Chen, Wen Ma, Jianing Huang & Jia Li. (2020) Drug-drug interaction between crizotinib and entecavir via renal secretory transporter OCT2. European Journal of Pharmaceutical Sciences 142, pages 105153.
Crossref
Crossref
Anne-Laure Clairet, Marie Boiteux-Jurain, Elsa Curtit, Marie Jeannin, Blandine Gérard, Virginie Nerich & Samuel Limat. (2019) Interaction between phytotherapy and oral anticancer agents: prospective study and literature review. Medical Oncology 36:5.
Crossref
Crossref
Shangying Chen, Sheng Yong Yang, Zhe Chen, Ying Tan, Yu Yang Jiang & Yu Zong Chen. (2018) Drug sales confirm clinical advantage of multi‐target inhibition of drug escapes by anticancer kinase inhibitors. Drug Development Research 80:2, pages 246-252.
Crossref
Crossref
A.A. Thai & B.J. Solomon. (2018) Alectinib as first-line therapy for ALK-rearranged NSCLC: a no-brainer?. Annals of Oncology 29:11, pages 2160-2162.
Crossref
Crossref
Rafael Reis, Laurence Labat, Marie Allard, Pascaline Boudou-Rouquette, Jeanne Chapron, Audrey Bellesoeur, Audrey Thomas-Schoemann, Jennifer Arrondeau, Frédérique Giraud, Jérôme Alexandre, Michel Vidal, François Goldwasser & Benoît Blanchet. (2018) Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients. Journal of Pharmaceutical and Biomedical Analysis 158, pages 174-183.
Crossref
Crossref
Xiaoyan Qi, Lin Zhao, Qiuping Zhao & Qiaoxia Xu. (2018) Simple and sensitive LC–MS/MS method for simultaneous determination of crizotinib and its major oxidative metabolite in human plasma: Application to a clinical pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis 155, pages 210-215.
Crossref
Crossref
Alesha A. Thai & Benjamin J. Solomon. (2018) Treatment of ALK-positive nonsmall cell lung cancer: recent advances. Current Opinion in Oncology 30:2, pages 84-91.
Crossref
Crossref
Tiziana Vavalà & Silvia Novello. (2018) Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy. Therapeutic Advances in Medical Oncology 10, pages 175883591878936.
Crossref
Crossref
Ka-Won Noh, Mi-Sook Lee, Seung Eun Lee, Ji-Young Song, Hyun-Tae Shin, Yu Jin Kim, Doo Yi Oh, Kyungsoo Jung, Minjung Sung, Mingi Kim, Sungbin An, Joungho Han, Young Mog Shim, Jae Ill Zo, Jhingook Kim, Woong-Yang Park, Se-Hoon Lee & Yoon-La Choi. (2017)
Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (
ALK
)
-
rearranged non-small cell lung cancer
. The Journal of Pathology 243:3, pages 307-319.
Crossref
Crossref
S. Wang, J. Chen, Z. Xie, L. Xia, W. Luo, J. Li, Q. Li & Z. Yang. (2017) Pulsatile crizotinib treatment for brain metastasis in a patient with non-small-cell lung cancer. Journal of Clinical Pharmacy and Therapeutics 42:5, pages 627-630.
Crossref
Crossref
Gaby A.M. Eliesen, Petra van den Broek, Jeroen J. van den Heuvel, Albert Bilos, Jeanne Pertijs, Joris van Drongelen, Frans G.M. Russel & Rick Greupink. (2017) Editor?s Highlight: Placental Disposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicological Sciences 157:2, pages 500-509.
Crossref
Crossref
Francesco Facchinetti, Giulio Rossi, Emilio Bria, Jean-Charles Soria, Benjamin Besse, Roberta Minari, Luc Friboulet & Marcello Tiseo. (2017) Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition. Cancer Treatment Reviews 55, pages 83-95.
Crossref
Crossref
Michaël Duruisseaux, Benjamin Besse, Jacques Cadranel, Maurice Pérol, Bertrand Mennecier, Laurence Bigay-Game, Renaud Descourt, Eric Dansin, Clarisse Audigier-Valette, Lionel Moreau, José Hureaux, Remi Veillon, Josiane Otto, Anne Madroszyk-Flandin, Alexis Cortot, François Guichard, Pascaline Boudou-Rouquette, Alexandra Langlais, Pascale Missy, Franck Morin & Denis Moro-Sibilot. (2017)
Overall survival with crizotinib and next-generation ALK inhibitors in
ALK
-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
. Oncotarget 8:13, pages 21903-21917.
Crossref
Crossref
Frank M. Balis, Patrick A. Thompson, Yael P. Mosse, Susan M. Blaney, Charles G. Minard, Brenda J. Weigel & Elizabeth Fox. (2016) First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children’s Oncology Group Phase 1/Pilot Consortium. Cancer Chemotherapy and Pharmacology 79:1, pages 181-187.
Crossref
Crossref
Yutaka Fujiwara, Akinobu Hamada, Hidenori Mizugaki, Hiroaki Aikawa, Toshiyuki Hata, Hidehito Horinouchi, Shintaro Kanda, Yasushi Goto, Kota Itahashi, Hiroshi Nokihara, Noboru Yamamoto & Yuichiro Ohe. (2016)
Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with
ABCB
1
polymorphism
. Cancer Science 107:8, pages 1117-1123.
Crossref
Crossref
Feng Qiu, Yanan Gu, Tingting Wang, Yingying Gao, Xiao Li, Xiangyu Gao & Shan Cheng. (2016) Quantification and pharmacokinetics of crizotinib in rats by liquid chromatography-tandem mass spectrometry. Biomedical Chromatography 30:6, pages 962-968.
Crossref
Crossref
K Venkatakrishnan, C Burgess, N Gupta, A Suri, T Takubo, X Zhou, D DeMuria, M Lehnert, K Takeyama, S Singhvi & A Milton. (2016) Toward Optimum Benefit‐Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles. Clinical and Translational Science 9:1, pages 9-22.
Crossref
Crossref